Annovis Bio – Lead Program to Treat Alzheimer’s and Parkinson’s Diseases

Dr. Maria Maccecchini, PhD, CEO of Annovis Bio discusses the company’s lead program ​ANVS401 that has shown that it lowers levels of neurotoxic proteins for both Alzheimer’s disease (AD) and Parkinson’s disease (PD) patients and improves cognition in AD patients and motor function in PD patients. 

Maria L. Maccecchini, Ph.D., Founder, President, CEO and Executive Board Member of Annovis Bio. Dr. Maccecchini founded Annovis in May 2008 to develop better therapeutics for Alzheimer’s, Parkinson’s and other neurodegenerative diseases. Was partner and director of two angel groups, Robin Hood Ventures and MidAtlantic Angel Group; Founder and CEO of Symphony Pharmaceuticals/Annovis a biotech company that sold in 2001 to Transgenomic; General Manager of Bachem Bioscience, the US subsidiary of Bachem AG, Switzerland and Head Molecular Biology Mallinckrodt; Dr. Maccecchini did one postdoc at Caltech and one at the Roche Institute of Immunology, her PhD in biochemistry is from the Biocenter of Basel with a two-year visiting fellowship at The Rockefeller University.

Liked it? Take a second to support healthprofessionalradio on Patreon!


Leave a Reply

You must be logged in to post a comment.